secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2021-08-23T23:59:59+00:00
Accession:  0001437749-21-020715
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart appoints Julie M. Cherrington, Ph.D. to Board of Directors
-----------------------------------------------------------------

- Dr. Cherrington appointed to Vaxart's Board and Audit Committee effective August 20, 2021.
- She receives annual cash retainers: $40k for Board, $7.5k for Audit Committee, plus time-based stock option for 65,700 shares vesting over 3 years.
- Dr. Cherrington is CEO of QUE Oncology, has held leadership roles at Gilead, SUGEN, and several oncology biotechs.
- Vaxart is developing oral tablet vaccines for COVID-19 and norovirus; Phase II COVID-19 trials expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774921020715/0001437749-21-020715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774921020715/vxrt20210820_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-21-020715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer